Influence of platelet-activating factor on cerebral microcirculation in rats: Part 1. Systemic application

Stroke

Volumn 30, Issue 4, 1999, Pages 873-879

  Uhl, Eberhard ^a   Pickelmann, Sven ^a   Baethmann, Alexander ^a   Schürer, Ludwig ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerebral circulation; Leukocytes; Platelet activating factor; Rats

Indexed keywords

BEPAFANT; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; WEB 2170BS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MICROCIRCULATION; CONTROLLED STUDY; DRUG INHIBITION; HEMOPERFUSION; HYPOTENSION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SHOCK; VASCULAR ENDOTHELIUM;

EID: 0032919557     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.4.873     Document Type: Article

References (29)

1. Braquet P, Hosford D. The potential role of platelet-activating factor (PAF) in shock, sepsis and adult respiratory distress syndrome (ARDS). Prog Clin Biol Res. 1989;308:425-439.
2. Lindsberg PJ, Hallenbeck JM, Feuerstein G. Platelet-activating factor in stroke and brain injury. Ann Neurol. 1991;30:117-129.
3. Bjork J, Smedegard G. Acute microvascular effects of PAF-acether, as studied by intravital microscopy. Eur J Pharmacol. 1983;96:87-94.
4. Bekker AY, Dillon PK, Paul J, Ritter AB, Duran WN. Dose-response relationships between platelet activating factor and permeability: surface area product of FITC-dextran 150 in the hamster cheek pouch. Microcirc Endothelium Lymphatics. 1988;4:433-446.
5. Dillon PK, Fitzpatrick MF, Ritter AB, Duran WN. Effect of platelet-activating factor on leukocyte adhesion to microvascular endothelium: time course and dose-response relationships. Inflammation. 1988;12: 563-573.
6. Kochanek PM, Nemoto EM, Melick JA, Evans RW, Burke DF. Cerebrovascular and cerebrometabolic effects of intracarotid infused platelet-activating factor in rats. J Cereb Blood Flow Metab. 1988;8:546-551.
7. Kawamura S, Schürer L, Goetz A, Kempski O, Schmucker B, Baethmann A. An improved closed cranial window technique for investigation of blood-brain barrier function and cerebral vasomotor control in the rat. Int J Microcirc Clin Exp. 1990;9:369-383.
8. Zeintl H, Sack FU, Intaglietta M, Messmer K. Computer-assisted leukocyte adhesion measurement in intravital microscopy. Int J Microcirc Clin Exp. 1989;8:293-302.
9. Sörensen J, Kald B, Tagesson C, Lindahl M. Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med. 1994;20:555-561.
10. Stahl GL, Craft DV, Lento PH, Lefer AM. Detection of platelet-activating factor during traumatic shock. Circ Shock. 1988;26:237-244.
11. Feuerstein G, Hallenbeck JM. Prostaglandins, leukotrienes, and platelet-activating factor in shock. Annu Rev Pharmacol Toxicol. 1987;27:301-313.
12. Lindsberg PJ, Jacobs TP, Paakkari IA, Hallenbeck JM, Feuerstein G. Effect of systemic platelet-activating factor (PAF) on the rabbit spinal cord microcirculation. J Lipid Mediat. 1990;2:41-58.
13. Lai F, Shepherd C, Cervoni P, Wissner A. Hypotensive and vasodilatory activity of (I) 1-O-octadecyl-2-acetyl-blycryl-3-phosphorocholine in the normotensive rat. Life Sci. 1983;32:1159-1166.
14. Siren AL, Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol. 1989; 257:H25-H32.
15. Handley DA, Lee ML, Saunders RN. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. Thromb Haemost. 1985;54:756-759.
16. Muacevic G, Heuer HO. Platelet-activating factor antagonists in experimental shock. Arzneimittelforschung. 1992;42:1001-1004.
17. Edwards RM, Trizna W, Feuerstein G. Platelet-activating factor (PAF) has no direct effect on rat intracerebral arterioles in vitro. J Lipid Mediat. 1991;3:161-165.
18. Uski TK, Reinstrup P. Actions of platelet-activating factor on isolated feline and human cerebral arteries. J Cereb Blood Flow Metab. 1990;10: 428-431.
19. Armstead WM, Pourcyrous M, Mirro R, Leffler CW, Busija DW. Platelet activating factor: a potent constrictor of cerebral arterioles in newborn pigs. Circ Res. 1988;62:1-7.
20. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of neutrophils to cultured human microvascular endothelial cells: stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest. 1989;83:637-646.
21. Springer TA. Adhesion receptors of the immune system. Nature. 1990; 346:425-434.
22. Schmid Schonbein GW, Usami GW, Skalak R, Chien S. The interaction of leukocytes and erythrocyres in capillary and postcapillary vessels. Microvasc Res. 1980;19:45-70.
23. Harlan JM. Leukocyte-endothelial interactions. Blood. 1985;65:513-525.
24. Ley K, Gaethgens P. Endothelial, not hemodynamic differences are responsible for preferential leukocyte rolling in rat mesenteric venules. Circ Res. 1991;69:1034-1041.
25. Gaboury JP, Kubes P. Reductions in physiologic shear rates lead to CD11/CD18-dependent, selectin-independent leukocyte rolling in vivo. Blood. 1994;83:345-350.
26. Goldsmith HL, Spain S. Margination of leukocytes in blood flow through small tubes. Microvasc Res. 1984;27:204-209.
27. Kumar R, Harvey SA, Kester M, Hanahan DJ, Olson MS. Production and effects of platelet-activating factor in the rat brain. Biochim Biophys Acta. 1988;963:375-383.
28. Schoettle RJ, Kochanek PM, Magargee MJ, Uhl M, Nemoto EM. Early polymorphonuclear leukocyte accumulation correlates with the development of posttraumatic cerebral edema in rats. J Neurotrauma. 1990;7:207-217.
29. Heuer HO, Casals Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther. 1990;255: 962-968.